Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
- Conditions
- Female Patients With Overactive Bladder Syndrome
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05946902
- Locations
- 🇨🇳
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan
TReating Incontinence for Underlying Mental and Physical Health
- Conditions
- Urinary Incontinence, UrgeOveractive BladderUrinary IncontinenceIncontinence, UrgeIncontinence, UrinaryIncontinence
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 270
- Registration Number
- NCT05362292
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome
- Conditions
- Overactive BladderObstructive Sleep ApneaOveractive Bladder Syndrome
- Interventions
- Other: Continuous positive airway pressure therapy (CPAP)
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Yuzuncu Yıl University
- Target Recruit Count
- 60
- Registration Number
- NCT05250245
- Locations
- 🇹🇷
Yuzuncu Yıl University, Van, Turkey
Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
- Conditions
- Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Kasr El Aini Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04500860
- Locations
- 🇪🇬
Samer Morsy, Cairo, Egypt
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- Conditions
- Overactive Bladder (OAB)
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 506
- Registration Number
- NCT03583372
- Locations
- 🇺🇸
Coastal Clinical Research Inc., Mobile, Alabama, United States
🇺🇸Downtown L.A. Research Center Inc., Los Angeles, California, United States
🇺🇸Women's Clinic of Lincoln PC, Lincoln, Nebraska, United States
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Device: solifenacinDevice: propiverine
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 1530
- Registration Number
- NCT03492281
- Locations
- 🇺🇸
Prime-Care Clinical Research, Laguna Hills, California, United States
🇺🇸KO Clinical Research, Fort Lauderdale, Florida, United States
🇺🇸Vital Pharm Research Inc., Hialeah, Florida, United States
the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery
- Conditions
- Pelvic Organ Prolapse
- Interventions
- Device: transvaginal synthetic mesh
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT02599311
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
- Conditions
- Overactive Bladder
- Interventions
- Drug: Placebo(For Detrusitol 2mg tablet)Drug: Placebo(For THVD-201)
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 384
- Registration Number
- NCT02485067
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea, Bucheon ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.